SG11202111720TA - Mrna formulation - Google Patents
Mrna formulationInfo
- Publication number
- SG11202111720TA SG11202111720TA SG11202111720TA SG11202111720TA SG11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA SG 11202111720T A SG11202111720T A SG 11202111720TA
- Authority
- SG
- Singapore
- Prior art keywords
- mrna formulation
- mrna
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19171323 | 2019-04-26 | ||
| PCT/EP2020/061477 WO2020216911A1 (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111720TA true SG11202111720TA (en) | 2021-11-29 |
Family
ID=66290283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111720TA SG11202111720TA (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362360A1 (en) |
| EP (1) | EP3958893A1 (en) |
| JP (1) | JP2022532038A (en) |
| KR (1) | KR20220023340A (en) |
| CN (1) | CN114096272A (en) |
| AU (1) | AU2020263948A1 (en) |
| BR (1) | BR112021021262A2 (en) |
| CA (1) | CA3138011A1 (en) |
| IL (1) | IL287560A (en) |
| MX (1) | MX2021013018A (en) |
| SG (1) | SG11202111720TA (en) |
| WO (1) | WO2020216911A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173474A1 (en) * | 2007-09-14 | 2017-05-31 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| ES2573458T3 (en) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Improvement of the stimulatory capacity of the T cells of cells presenting human antigen and their use in vaccination |
| ES2666380T3 (en) | 2013-11-12 | 2018-05-04 | Vrije Universiteit Brussel | RNA transcription vector and its uses |
| EP3582790A4 (en) * | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | High potency immunogenic compositions |
-
2020
- 2020-04-24 AU AU2020263948A patent/AU2020263948A1/en active Pending
- 2020-04-24 CA CA3138011A patent/CA3138011A1/en active Pending
- 2020-04-24 KR KR1020217038364A patent/KR20220023340A/en unknown
- 2020-04-24 US US17/604,559 patent/US20220362360A1/en active Pending
- 2020-04-24 BR BR112021021262A patent/BR112021021262A2/en unknown
- 2020-04-24 MX MX2021013018A patent/MX2021013018A/en unknown
- 2020-04-24 JP JP2021563262A patent/JP2022532038A/en active Pending
- 2020-04-24 CN CN202080038101.1A patent/CN114096272A/en active Pending
- 2020-04-24 SG SG11202111720TA patent/SG11202111720TA/en unknown
- 2020-04-24 WO PCT/EP2020/061477 patent/WO2020216911A1/en active Search and Examination
- 2020-04-24 EP EP20721229.1A patent/EP3958893A1/en active Pending
-
2021
- 2021-10-25 IL IL287560A patent/IL287560A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022532038A (en) | 2022-07-13 |
| US20220362360A1 (en) | 2022-11-17 |
| MX2021013018A (en) | 2022-03-11 |
| CA3138011A1 (en) | 2020-10-29 |
| AU2020263948A1 (en) | 2021-12-23 |
| BR112021021262A2 (en) | 2021-12-21 |
| CN114096272A (en) | 2022-02-25 |
| IL287560A (en) | 2021-12-01 |
| WO2020216911A1 (en) | 2020-10-29 |
| KR20220023340A (en) | 2022-03-02 |
| EP3958893A1 (en) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276011A (en) | Group b adenovirus-containing formulation | |
| IL282617A (en) | Aerosolisable formulation | |
| IL282523A (en) | Aerosolisable formulation | |
| IL282567A (en) | Aerosolisable formulation | |
| IL282589A (en) | Aerosolisable formulation | |
| IL282461A (en) | Aerosolisable formulation | |
| IL282546A (en) | Aerosolised formulation | |
| IL290447A (en) | Pharmaeutical composition comprising ensifentrine | |
| IL282697A (en) | Aerosolisable formulation | |
| IL282392A (en) | Aerosolisable formulation | |
| GB201816447D0 (en) | Formulation | |
| IL282585A (en) | Aerosolised formulation | |
| EP3632429A4 (en) | Amyloid- protein level decreasing agent | |
| IL284688A (en) | Formulation | |
| GB201913756D0 (en) | Contrast agent | |
| GB201807312D0 (en) | Formulation | |
| IL280138A (en) | Aerosolisable formulation | |
| GB201913232D0 (en) | Aerosolisable formulation | |
| GB201813229D0 (en) | Formulation | |
| IL287560A (en) | Mrna formulation | |
| GB2587402B (en) | Formulation | |
| GB201906242D0 (en) | Aerosolisable formulation | |
| GB201900658D0 (en) | Formulation | |
| IL284573A (en) | Mrna vaccine | |
| GB201817866D0 (en) | Aerosolisable formulation |